

**BACKGROUND:**

- Born in India. Came to Canada in 1966 and grew up in Fredericton, New Brunswick, Canada
- Graduated in the top 10 in 1987 from Dalhousie Medical School, Halifax, Nova Scotia
- Completed Internal Medicine and Cardiology residency training at the University of Toronto
- Completed Cardiology Clinical Research Fellowship at St. Michael's Hospital, Univ of Toronto, 1994
- Staff Cardiologist, Rouge Valley Health System, Centenary site, Toronto, ON, 1994-2002
- Relocated to Atlanta, GA, June 2002, Cardiologist, Northside Cardiology 2002-10, Atlanta Heart Specialists -2010- 2020, now with NSC Cardiology /NSC Research and USHV

**KEY CURRENT POSITIONS:**

- Staff cardiologist, Northside Forsyth Hospital, Emory Johns Creek Hospital
- Director, Clinical Research Program, NSC Research/NSC Cardiology
- Clinical Assistant Professor – Medical College of Georgia at Augusta University, Augusta, GA
- Clinical Assistant Professor- College of Health Professions, Mercer University, Atlanta, GA
- Senior Clinician Scientist /Director– Canadian Collaborative Research Network (CCRN)

**KEY PAST POSITIONS:**

- Clinical Assistant Professor – Emory University, Div of Cardiology, Atlanta, Georgia
- Chair, Section of Cardiology, Northside Hospital (Atlanta and Forsyth campus)
- Vice Chair- St Josephs Research Institute, Board Member SJTRI
- American College of Cardiology – Atlanta representative on ACC-GA Chapter Council
- Secretary and National Executive Council Member, Canadian Cardiovascular Society (CCS)
- Lecturer, Division of Cardiology, Department of Medicine, University of Toronto
- Chair and founding member, Greater Toronto Area Community Cardiologists (GTACC)
- President of the Medical Staff Society, RVHS- Centenary Health Centre
- Board of Governors, Medical Staff Society Rep, RVHS-Centenary Health Centre
- Board of Directors, Physician Representative, RVHS-Centenary Health Centre Foundation
- Medical Director, Pacemaker/ICD Program and Cath Lab, RVHS-Centenary Health Centre

**KEY PROFESSIONAL MEMBERSHIPS:**

- Fellow of the American College of Cardiology (FACC), American Heart Association (FAHA)
- Fellow Royal College of Physicians & Surgeons (FRCPC), Canadian Cardiovascular Society (FCCS)
- Board Certified in Cardiology and Internal Medicine both in Canada and the United States.

**RESEARCH EXPERIENCE:**

- Published over 30 articles and 70 abstracts on a wide range of topics in cardiology
- Principal site investigator on over 200 key national and international clinical trials.
- Actively designs and conducts independent investigator initiated clinical research
- Former Member St Joseph's Hospital IRB, SJRI, SJTRI and Northside Cardiac Research group

**AWARDS AND SCHOLARSHIPS:**

- Recipient of numerous awards and scholarships throughout high school, undergraduate and postgraduate training for academic merit and leadership skills
- Recipient of many awards of recognition for hospital and community service in Toronto
- Recipient of multiple research awards and grants for ongoing projects; focus on South Asian and other ethnic heart disease, health outcomes research and heart failure.

**MISCELLANEOUS INFORMATION:**

- Enjoys teaching medical students, NP and PA students, and post-graduate trainees
- Invited to deliver lectures on various topics within the field of cardiovascular medicine.
- Outside interests include live theatre, movies, music, travel, team sports, skiing and golf

# **Curriculum Vitae–Narendra Singh**

## **PERSONAL DATA**

**Date of Birth** June 10, 1963  
**Place of Birth** Saraiya, India

**Children** 3 sons, 1 daughter  
**Citizenship** American/Canadian  
**Languages** English, some Hindi



### **CORPORATE ADDRESS**

NSingh Consulting LLC, 3325 Piedmont Road #2105  
Atlanta, GA 30305 Email [narendra.singh@yahoo.com](mailto:narendra.singh@yahoo.com)  
[www.heartdrsingh.com](http://www.heartdrsingh.com)

### **OFFICE ADDRESS**

NSC Cardiology – 5400 Laurel Springs Parkway Ste 1401, Johns Creek, GA 30024  
(P) 678-208-0165 (F) 888-814-0852 E-mail- [DrSingh@nsccardiology.com](mailto:DrSingh@nsccardiology.com)  
Satellite office – Cumming, GA 30041 for more info [www.nsccardiology.com](http://www.nsccardiology.com)  
[Also work with Osler Cardiology Associates and Brampton Research Associates in Canada](#)

### **HOSPITAL AFFILIATIONS**

Northside Forsyth Hospital and Emory Johns Creek Hospital

## **BRIEF CHRONOLOGY**

**2020 – Present** – Cardiologist, Research Director, NSC Cardiology/NSC Research, Atlanta, Georgia  
**2020- Present** – Clinical Assistant Professor, College of Health Professions, Mercer Univ, Atlanta, GA  
**2012- Present** – Clinical Assistant Professor, Medical College of Georgia at Augusta University  
2010 – 2020 – Cardiologist, Research Director, Atlanta Heart Specialists LLC, Atlanta, Georgia  
2002-2011- Clinical Assistant Professor, Emory University, Div of Cardiology, Atlanta, GA  
2002-2010- Cardiologist/Partner/Research Director, Northside Cardiology, PC, Atlanta, Georgia  
1994 -2002 - Staff Cardiologist, Dept.of Medicine, RVHS - Centenary site, Toronto, Ontario  
1994 -2002 - Lecturer, Department of Medicine, University of Toronto, Toronto, Ontario  
1993-1994 - Completed Cardiology Research Fellowship at St. Michael's Hospital, Toronto.  
1991-1993 - Completed residency training in Adult Cardiology at the University of Toronto  
1988-1991 - Completed residency training in Internal Medicine at the University of Toronto  
1987-1988 - Completed rotating internship at St. Michael's Hospital, University of Toronto.  
1983-1987 - Graduated from Dalhousie University Medical School, Halifax, Nova Scotia.  
1981-1983 - Completed 2 yrs of a Bachelor of Science degree, Dalhousie Univ, Halifax, N.S.  
1978-1981 - Graduated from Fredericton High School, Fredericton, New Brunswick.

## ***Summary of Public School and Undergraduate Training (1975-1987)***

### **1. Academic Performance**

**1983-1987-** Dalhousie University, Faculty of Medicine, Graduated with M.D. degree, ranking 10th out of 98 students

- Distinctions were obtained in 14 courses and the following clerkship rotations:

*Medicine, Pediatrics, Surgery*

- Clerkship Electives were done at:

- *Toronto General Hospital*, Toronto, Ontario, *Emergency Medicine*

Supervisors: Dr. B. Rowat, Dr. L. Greenspan

- *Brigham and Women's Hospital*, Boston, Massachusetts, *Cardiology*

Supervisors: Dr. B. Lown, Dr. T. Graboys

- Please note ; University Transcripts are available upon request.

**1981-1983-** Dalhousie University, 2yrs of a Bachelor of Science, Biochemistry Major, Overall G.P.A. = 3.7 = A obtained early admission to medical school

**1978-1981-** Graduated from Fredericton High School with second highest academic standing.

**1975-1978-** Graduated from Nashwaaksis Junior High School with highest academic standing.

### **2. Extra-Curricular Involvement**

- Selected student rep on the Admissions Committee for the Faculty of Medicine -1986
- Dalhousie Medical Student Society (DMSS), representative on the Professional Assoc. of Residents and Interns for the Maritime Provinces (PARI-MP) Council - 1987
- Chairperson of the DMSS constitutional committee.-1987
- Course representative for my class in - Pharmacology (2nd year); Human Sexuality, Pediatrics, Medicine, Surgery, Family Medicine (3rd year)-1986-87
- Organizing Committee for the DMSS annual charity auction and book sale -1985-86
- Lab Instructor for Biology 1000 course. 1984-85
- Treasurer of the Dalhousie Science Society (DSS)-1984
- DSS Representative for the Dalhousie Association of Biology Students-1983
- Student rep on the Dalhousie undergraduate scholarship committee.1982-83
- Student representative on the Dalhousie undergraduate curriculum committee.1982
- President of one of the houses in the Howe Hall Men's Residence Complex and House representative on residence council -1982-83
- Treasurer of the high school Student Council -1981
- Managing Editor of the High School Paper-1980-81
- Chairperson of the high school's first Annual Year End Activities Banquet -1981
- Model Parliament treasurer and participant- 1979-81
- Student Council Class Representative-1979-80
- Member of the stage crew for the high school's annual musical production-1980-81
- Active in many intramural sports activities eg. hockey, soccer, baseball, and football.

### 3. **Major Awards/Scholarships**

- Selected to the Alpha Omega Alpha (ΑΩΑ) Honour Medical Society recognizing "Academic Achievements as well as Outstanding Personal Qualities, Contributions, and Achievements"-1987
- Awarded \$1000 Proctor and Gamble Award of Excellence at Dalhousie Univ in recognition of "Outstanding Academic Achievement and Extra-Curricular Involvement"-1986
- Awarded \$500 scholarship for 3rd highest academic standing in 2nd year med -1985
- Awarded CV Mosby Book Prize for Scholastic Excellence in 2nd year medicine-1985
- Awarded conference trip-"Research Frontiers in Diabetes Mellitus" in Toronto-1984
- Awarded \$250 scholarship for fifth highest academic standing in 1<sup>st</sup> yr medicine-1984
- Awarded \$3000 summer research studentship, funding by the Nova Scotia branch of the Canadian Diabetic Association-1984
- Awarded \$1000 entrance scholarship into the Faculty of Medicine-1983
- Awarded \$600 in-course scholarship by the Faculty of Science-1983
- Presented the Howe Hall Outstanding Leadership Award in recognition of accomplishments achieved as president of Studley House-1983
- Presented appreciation plaque by residents of Studley House, Men's Residence-'83
- Awarded \$1300 in-course scholarship by the Faculty of Science -1982
- Awarded \$2000 Dalhousie University's top entrance scholarship - 1981
- Awarded \$1000 Regent Mall Scholarship -based on student involvement and high academic standing-1981
- Awarded Birk's Medal for Leadership in Student Activities at F'ton High School-1981
- Presented the Citizenship Award for "Highest Contribution to the extra-curricular program at Fredericton High School"-1981
- Awarded Victoria Lodge Prize for the second highest academic standing at high school graduation (94%)-1981
- Presented three black "F" awards for academic excellence and outstanding extra-curricular involvement over 3 years of high school-1981
- Awarded C.W. Hall's Bookstore prize for highest standing in Grade 12 History –1981

### ***Summary of Undergraduate Research Experience (1982-1987)***

#### **Summer 1984**

Dalhousie University - Studied the effects of oral hypoglycemics on skeletal muscle insulin sensitivity and responsiveness.

*Reference* - Dr. M.H.Tan, Chief of Medicine, Halifax Infirmary Hospital (902) 421-7510

#### **Summer 1982,1983**

Agriculture Canada - Research into the effects of abiotic and agronomic factors on population dynamics of aphid predators in potato fields.

*Reference* - Dr. G. Boiteau, Division of Plant Pathology, Fredericton, N.B. (506) 452-3260

#### **1982-1983**

Dalhousie University - Research into the Alcohol Expectancy Effect and its influence on motor skills performance.

*Reference* - Dr. P. Dunham, Department of Psychology, Halifax, N.S. (902) 424 –2211

**1. Postgraduate Training**

- 1993 -'94 -** (PGY-7) Clinical Research Fellowship, University of Toronto, Ontario  
*Supervisor* - Dr. Anatoly Langer, St. Michael's Hospital  
*Projects* - Post MI Outcomes and Resource Utilization Analysis, Heart - Rate Variability Post MI, ST Shift in Unstable Angina, Time to Treatment  
Also did diagnostic cardiac catheterizations 1/2 day /week at SMH/TGH.
- 1991 -'93 -** (PGY- 5,6) Adult Cardiology at the University of Toronto, Ontario  
base hospitals - St. Michael's Hospital, and The Toronto Hospital, Toronto General and Western divisions  
electives done -pediatric cardiology, adult congenital heart disease, pre - cardiac transplantation, diagnostic cardiac catheterization
- 1988 -'91-** (PGY-2,3,4) Core Internal Medicine at the University of Toronto, Ontario  
base hospitals - St. Michael's Hospital, and The Toronto Hospital, Toronto General and Western divisions
- 1987 -'88 -** (PGY-1) Rotating Internship at St. Michaels Hospital / Hospital for Sick Children, University of Toronto, Ontario. Rotations as follows:  
8 weeks; pediatrics, medicine, ob/gyn, psychiatry, emergency medicine.  
4 weeks; medical/surgical ICU, orthopedics, radiology

**2. Post-Grad Awards/Scholarships**

- Awarded Heart and Stroke Foundation of Canada Research Fellowship Award (\$42,585) for 1994-'95 (declined as I accepted a staff position)
- Awarded second prize in Annual Higgins' Resident Research Day competition - 1994
- Awarded Univ of Toronto Pettit Research Fellowship, Dept of Medicine (\$41,295)-1993
- Awarded 1st prize in the U.B. Cardiology Resident Research Day competition - 1993
- Awarded second prize in Annual Higgins' Resident Research Day competition - 1992
- Awarded third prize in Annual Higgins' Resident Research Day competition - 1990

**3. Other Post-Grad Activities**

- Cardiology Resident rep, Div of Cardiology Postgraduate Training Committee 1991-93
- Resident coordinator for the Royal College Oral Exams at the Toronto Hospital -1991
- R3 rep on the Residency Training Committee for the Toronto Hospital - 1990- '91
- Representative on Dept. of Medicine On-Site Evaluation committee; 1988- 1991
- Representative on the Interns Education and Liaison Committee for 1987-88.

**4. Graduate Courses**

- Introduction to Clinical Epidemiology Univ of Toronto (4.0 GPA) Jan 1994
- Accepted in U of T Masters Program in Clinical Epidemiology (declined) Jul 1994

## **Summary of Professional Achievements**

**(1987 - present )**

### **1. Hospital Appointments**

- **Currently;** Staff Cardiologist, Northside Hospital Forsyth July 2002-**present**  
Staff Cardiologist, Emory Johns Creek Hospital, January 2007 –**present**
- **Previous;** Staff Cardiologist, RVHS-Centenary site, July 1994 to June 2002  
Staff Cardiologist, Dekalb Medical, July 2010 –2020  
Staff Cardiologist, Grady Memorial, July 2002 –2009  
Staff Cardiologist, Northside Hospital Duluth July 2020-2022  
Staff Cardiologist, Northside Hospital Cherokee July 2021-2022  
Staff Cardiologist, Emory St. Joseph's Hospital, July 2002-2024  
Staff Cardiologist, Piedmont Hospital Atlanta July 2020 –2021

### **2. Current Medical Licenses**

- Province of Ontario CPSO Registration # 58438
- State of Georgia Medical License # 37905  
DEA# BS7629782  
NPI # 1760477202

### **3. Major Licensing Exam Results**

- |                                                                   |                                  |
|-------------------------------------------------------------------|----------------------------------|
| • ABIM Certified Cardiovascular Disease/ACC CMP                   | <b>Participating in MOC</b>      |
| • ABIM Recertification Exam in Cardiovascular Disease             | <b>Passed April 2015</b>         |
| • ABIM Recertification Exam in Cardiovascular Disease             | <b>Passed May 2005</b>           |
| • NASPE-Special Competency Cardiac Pacing & AICD                  | <b>Passed Sept 1999</b>          |
| • Certification Board of Nuclear Cardiology Exam                  | <b>Passed Oct 1998, Dec 2007</b> |
| • ABIM Certifying Exam in Cardiovascular Disease                  | <b>Passed Nov 1995</b>           |
| • Royal College Exams for Certificate of Competence in Cardiology | <b>Passed Nov 1993</b>           |
| • Royal College Oral Exams in Internal Medicine - F.R.C.P.(C)     | <b>Passed June 1992</b>          |
| • American Board of Internal Medicine (ABIM) Certifying Exam      | <b>Passed Sept 1991</b>          |
| • Royal College Written Exams in Internal Medicine                | <b>Passed Sept 1990</b>          |
| • FLEX Components I and II (Michigan)                             | <b>Passed June 1988</b>          |
| • Licensing Exam -Medical Council of Canada -LMCC                 | <b>Passed May 1987</b>           |

### **4. Key Professional Memberships**

- Fellow, American Heart Association (FAHA)
- Fellow, American College of Cardiology (FACC)
- Fellow, Royal College of Physicians of Canada, (FRCP(C))
- Fellow, Canadian Cardiovascular Society (FCCS)
- Member, Medical Association of Georgia (MAG)
- Member, Ontario Medical Association (OMA)
- Member, College of Physicians and Surgeons of Ontario (CPSO)
- Member, European Society of Cardiology (ESC)

### **5. Other Interests**

- Active in the organization of South Asian multicultural events, charity
- Enjoy reading/audiobooks, live theatre, movies, music, travel, dining, skiing, golf

## **Summary of Committee Memberships/Panels/Working Groups (1994 - present)**

### **Hospital: Current Positions:**

none

### **Hospital: Past Positions – Atlanta, Georgia:**

Chief, Section of Cardiology, Northside Hospital (main campus and Forsyth) 2004-2006  
Northside Hospital Cardiac Research Subcommittee –2003-2010  
Northside Forsyth PCI Subcommittee-2009-2010  
Northside Hospital Cardiology Executive Committee – 2005- 2006  
St. Joseph's Hospital Women and Heart Disease Board – 2006-2008  
Clinical Methods Coordinator for Emory Univ Medical Students – NSH –2002- 2008  
St. Joseph's Hospital Research Institute – Vice Chair – 2008 – 2009  
St. Josephs Hospital CV Partners LLC- Operations and QA committee 2009  
St. Josephs Hospital Heart Failure Advisory Board- 2005-2009  
St. Josephs Hospital Translational Research Institute- Board Member- 2009  
St. Josephs Hospital Institutional Review Board- member -2008-2009

### **Hospital: Past Positions in Toronto, Canada:**

Medical Director – Scarborough Cardiology Research Organization, 1999 - 2002  
Medical Director - Pacemaker /ICD Program, 1995-2002  
Medical Director – Cardiac Cath Lab, 1999-2001  
Chairperson - Cardiac Care Educational Rounds, 1995-2002  
Chairperson- Data Mgmt and Advisory Committee, C.A.R.E. Clinic, 2000- 2002  
Chairperson, MAC Education Committee, 1997- 1999  
Chairperson, Cardiac Care Program Quality Assurance, 1995-1998  
Chairperson – Cardiac Program Endowment Fund Committee, 1999-2001  
Board Member, Physician Rep - Board of Directors, CHC Foundation, 1997-2001  
Physician Rep-Major Gifts Committee CHC Foundation, 1997- 1999  
President, Medical Staff Society (MSS), 1996-1997  
Vice-President, Medical Staff Society, 1995-1996  
Secretary - Medical Staff Society, 1994-1995  
MSS Rep, Board of Governors, 1995-1997  
MSS Rep-Strategic Planning committee, 1996-1997, Credentials committee, 1996-1997  
MSS Rep- Medical Advisory Committee (MAC), 1995-1997, Finance Committee, 1995-1996  
Secretary, Dept of Medicine Business Meetings, 1994-1995  
Member - MAC Research Committee, 1995-1999  
Cardiologist Rep, Medical Program Clinical Management Committee, 1997-1999  
Dept of Medicine Rep - Cardiac Arrest Committee, 1994-1999  
Cardiac Program Rep on MAC Quality Assurance Committee - 1996-1997  
Cardiologist Rep, Cardiac Care Community Advisory Committee - 1996-2002  
Member-Annual Cardiology Day of Excellence Planning Committee, 1998-2002  
Cardiologist Rep, Cardiac Care Teaching Committee, 1994-1997  
Medical Program Representative - MAC Quality Assurance Committee, 1994-1995.  
Member- Annual Clinic Update Day organization committee, 1994-1996  
Physician Representative, Medical Program Utilization Committee, 1995-1996  
Member- Cardiac Rehabilitation Development Committee, 1994-1996  
Member - Cardiac Program Management Committee, 1996- 2002  
Member - Cardiac Diagnostics , Clinical Cardiac Care , Pacemaker/ICD Committee, 1994-2002

## **Summary of Committee Memberships/ Panels/Working Groups (1994 - present)**

### **Regional- Current Positions in Georgia**

none

### **Regional- Past Positions in Georgia**

Atlanta Representative – GA chapter ACC Council – 2008-2014  
Member - Kaiser Permanente CHF/CAD Working Group 2002-2006  
Member – AHA board of directors, Metro Atlanta Division 2005-2008  
Chair ACC-Georgia – Annual Scientific Sessions CME Planning Committee 2005-2010

### **Regional- Past Positions in Ontario, Canada:**

Member, GTACC/Uof T Steering Committee 1999-2000  
Chair, GTACC Informatics Committee, 1999 -2001  
Chair - GTACC (Greater Toronto Area Community Cardiologists Association) 1996-1999  
Executive Committee Member - GTACC, 1995- 2001  
Medical Advisor - Scarborough Heart Health Network, 1995 - 1998  
Co-Chair, GTACC Summer Retreat 1997  
Co-Chair, GTACC/Univ of Toronto Summer Retreat 1998  
Chair, Medtronic Ontario Physician's Pacemaker Symposium, 1998  
Chair, Bayer Cardiology Weekend Retreat, 1999  
Planning Committee, St Michael's Annual Cardiology for the Practitioner Day –1998  
Planning Committee, GTACC/Univ of Toronto Summer Retreat 1999, 2000,2001, 2002  
Planning Committee, GTACC Fall Retreat 1999,2000,2001,2002  
Planning Committee, GTACC Clinical Research Symposium, 2000,2001  
Member – Advanced Cardiac Services Task Force 1997-2002

### **National/International – Current Positions in USA:**

Director – SANSAR - South Asian Network Supporting Awareness and Research 2014-**Present**  
Director – CCRN USA- Collaborative CME and Research Network 2010-**Present**

### **National/International – Past Positions in Canada:**

Panelist-Ask the Expert - Diabetes and Ethnicity, AHA Scientific Sessions,2012  
Panelist- Risk Stratification in a Multicultural Society, CCS Scientific Sessions, 2010  
Panelist - Coronary Heart Disease in South Asians, AHA Scientific Sessions, 2005  
Panelist - Coronary Heart Disease in South Asians, CCS Scientific Sessions, 2006  
Member – Am College of Cardiology, Assessment Working Group, 2007-2010

### **National/International – Past Positions in Canada:**

Secretary, Canadian Cardiovascular Society (CCS) 2000- 2002  
Executive Committee, Canadian Cardiovascular Society (CCS) 2000- 2002  
Executive Committee, Canadian Cardiovascular Academy, 2000 –2002  
Council Member, Canadian Cardiovascular Society (CCS) 1999- 2002  
Chairperson, Membership Committee CCS, 2000-2002  
Member, CCS Sponsorship Working Group, 1999  
Member, CCS Nominating Committee, 1999, 2000, 2001  
Co-Chair, St. Jude's Medical 1st Annual Canadian Arrhythmia Symposium, 1998  
Co-Chair, St. Jude's Medical 2nd Annual Canadian Arrhythmia Symposium, 1999  
Co-Chair, St. Jude's Medical 3<sup>rd</sup> Annual Canadian Arrhythmia Symposium, 2000  
Co-Chair, St. Jude's Medical 4th Annual Canadian Arrhythmia Symposium, 2001  
Primary panel, CCS Consensus Conference on Cardiac Transplantation, 2001  
Co-chair, CCS Satellite Symposium – Metabolic syndrome - 2002  
Co-chair, CCS Community Cardiologist Forum – 2001



## ***Summary of University Clinical Teaching Experience (1994- present )***

### **Atlanta Teaching;**

- Mercer and Augusta University PA Students - cardiology electives
- PCOM osteopathic students- Suwanee Campus- cardiology electives
- 2<sup>nd</sup> yr Emory Medical students – Clinical Methods Course
- Emory Cardiology Fellows – Grady Memorial Hospital Cardiology Clinic
- Emory PA students doing community cardiology electives
- 3<sup>rd</sup> and 4<sup>th</sup> yr medical students doing community cardiology electives

### **University of Toronto Teaching;**

- Clinical Clerk Seminars - “Congestive Heart Failure”, St. Michael’s Hospital, 1995-1996
- Ambulatory Clinic Experience for cardiology fellows, 1994-2002
- Community Cardiology Elective for cardiology fellows, 1994-2002
- Community Cardiology Elective for 3<sup>rd</sup> and 4<sup>th</sup> yr medical students, 1994-2002
- “Health in the Community” Elective preceptor –1999-2000

## ***Summary of Special Training /Certification (1994 - present )***

- **1995-1996** -Completed CMA- Physician Management Institute (PMI) program (courses I-IV)
- **1994-1997**- Advanced Pacemaker Function Courses with Medtronic and St.Judes Medical
- **1995**- HP - Stress Echo techniques, interpretation and utilization course
- **1996**- ICD Training courses with CPI, Medtronic and Teletronics
- **1997**- Indiana University, Interpretive Stress Echo Course
- **1998**- Am Soc Nuclear Cardiology, 3rd Annual Tutorial in Nuclear Cardiology
- **2001**- certification with Datascope on IABP insertion
- **2002**- certification with St Judes Medical on Angioseal closure device
- **2003**- certification with Duett vascular closure device
- **2003**- certification with St Judes Medical, Pacemaker Implantation Course
- **2006**- HRS –ICD/CRT Device Implantation and follow up course
- **2007**- Am Soc Nuclear Cardiology, 7th Annual Tutorial In Nuclear Cardiology
- **2008**- CTA Course, Denver, Level II certification
- **2020**- NAVIX Peripheral Vascular Ultrasound Interpretations Course

## ***Summary of Group Practice Involvement (2002 - present )***

- Physician Manager of Diagnostic Lab, Northside Cardiology PC – 2002-2005
- Director of Cardiac Research, Northside Cardiology PC- 2003-2010
- Physician Manager of Website, Northside Cardiology PC, 2004-2008
- Director of Cardiac Research, Atlanta Heart Specialists LLC- 2010-2020
- Director of Cardiac Research, NSC Cardiology/NSC Research 2020 - present

## ***Summary of Medical Industry Involvement (1994 - present )***

|         |                                                       |
|---------|-------------------------------------------------------|
| 1998-99 | Cardiology Preceptorship Experience – Searle Canada   |
| 1999    | Contributor, Canadian Journal of CME                  |
| 1998    | Regional Lipid Advisory Board, Merck Canada           |
| 1999    | Cardiology Consultant, Drug Intelligence Inc, Toronto |
| 2000    | National Standard Order Advisory Panel, Sanofi Canada |
| 2001-03 | National CAD Advisory Board, Pfizer Canada            |
| 2001    | National Cardiac Advisory Board, Biovail Canada       |

**Ongoing** – active within pharma/device industry and professional medical organizations as a speaker, consultant, facilitator and CME organizer.

Regular Webcast and Podcast Speaker with MD Learn and CCRN

### **Current Speakers Bureau;**

**Regional** – Amgen, Astra Zeneca,

**National** – Bayer, Boehringer Ingelheim, Novo Nordisk, Milestones

Have served on over 100 national and regional Speaker's Bureau and advisory boards

## ***Summary of Internal Hospital Publications (1994 - present)***

### **Contributing Author**

|      |                                                           |
|------|-----------------------------------------------------------|
| 1994 | Cardiac Care Program Strategic Plan                       |
| 1995 | Cardiac Care Program Strategic Plan Update                |
| 1995 | 3M Quality Healthcare Award - Your Heart is in Good Hands |
| 1995 | A Proposal to Establish A Cardiac Rehabilitation Program  |
| 1996 | Cardiac Care Program Strategic Plan Update                |
| 1996 | Regional Cardiac Care Center Proposal                     |
| 1997 | Cardiac Care Program-Strategic Plan                       |
| 1997 | Cardiac Care Hospital Accreditation Document              |
| 1998 | Regional Advanced Cardiac Services Proposal               |
| 1998 | Cardiac Care Program Strategic Plan                       |
| 1999 | High Risk Cardiac Intervention Service Proposal           |
| 1999 | Response to CCNO on PM/ICD Services at CHC                |

### **Principal Author**

|      |                                                                                   |
|------|-----------------------------------------------------------------------------------|
| 1995 | Dept of Medicine Annual QA Report                                                 |
| 1996 | Dept of Medicine Annual QA Report                                                 |
| 1996 | Effect of Early Ambulation on Hematoma Formation and Vascular Complications Study |
| 1996 | Cardiac Care Program Annual QA Report                                             |
| 1996 | Implantable Cardioverter Defibrillator Follow-up Proposal                         |
| 1997 | Differential Effects of ACEI on QOL and exercise in Cardiac Rehabilitation Study  |
| 1998 | Your Heart Is In Good Hands - Cardiac Care Program Brochure                       |
| 1998 | Cardiac Care Program Annual QA Report                                             |
| 1998 | Dept of Medicine – CME Maintenance of Competency Policy                           |

## **Summary of Clinical Research Trials Participation (1994- present )**

### **Principal Site Investigator- USA**

IRIS- rosuvastatin vs atorvastatin in South Asians, one of the top enrolling US sites  
ACCOMPLISH- outcomes trial using combination antihypertensives  
EVEREST- tolvaptan in acutely decompensated CHF  
OPTIMIZE-HF registry- in hospital CHF registry  
LIFE- Guidant pacemaker trial  
AWARE- Guidant pacemaker trial  
Affects Registry- outpt atrial fibrillation registry  
ULTRA- Guidant pacemaker trial  
RELY- dabigitran vs warfarin in atrial fibrillation  
TIMI 42 IMPROVE IT- ezetemibe on top of simvastatin in acute coronary syndrome  
RED-HF- darbopoeitin in CHF pts  
LTAP- Pfizer lipid management registry  
CLEAR- Biotronik CLS technology pacemaker trial  
TIMI 46 ATLAS- rivaroxaban dosing study in acute coronary syndromes  
CURRENT OASIS 7- high dose clopidogrel and ASA in ACS, *4<sup>th</sup> highest enroller in the USA*  
RIVAL – radial vs femoral PCI in ACS pts  
OMACOR-AFIB- high dose omega 3's in atrial fib- *top enrolling site in the study*  
RATE REGISTRY- St Judes pacemaker trial, *15<sup>th</sup> highest enrolling site*  
ASCEND HF- neseritide in acutely decompensated CHF  
TRILOGY-ACS- prasugrel vs clopidogrel in medically managed ACS  
TIMI 50 TRA-2P- vorapaxar in stable atherosclerotic disease, *top enrolling site in the USA*  
NATURE- Sorin pacemaker trial, *tied for highest enrolling USA site*  
Dal outcomes trial- dalcetrapib in ACS  
TIMI 48 ENGAGE–AF- edoxaban in atrial fib, *4<sup>th</sup> highest enrolling site in the USA*  
ALTITUDE- aliskiren outcomes trial in diabetic hypertensives  
TIMI 52 SOLID – LpPLA2 inhibitor darapladib in ACS pts  
BRADY-CARE- St Judes pacemaker trial  
EMERALD- Sorin pacemaker trial  
TIMI 54 PEGASUS- ticagrelor in chronic CAD – *silver medal enrolling site*  
PALLAS- dronedarone in permanent atrial fibrillation  
ASPECT- apadenosan vs adenosine in nuclear imaging  
SAVOR TIMI 53- saxagliptin in diabetes and CAD –*high enrolling site despite late participation*  
ASPECT II- apadenosan vs adenosine in nuclear imaging  
REVEAL TIMI 55/HPS3 – ancetrapib/atorvastatin in CAD and high risk diabetics  
DALOUTCOMES II– dalcetrapib in stable CAD and diabetics – *top enrolling site worldwide*  
REDUCE-IT- EPA ethyl esters in CAD and high risk diabetics – *high enrolling site*  
CANTOS – canakinumab IL-1 monoclonal antibody in post MI pts with high CRP  
Takeda angina – febuxostat in chronic angina patients  
ODYSSEY Longterm- PCSK9 inhibitor in stable CAD – *high enrolling site in USA*  
ODYSSEY Outcomes- PCSK9 inhibitor in ACS pts - *high enrolling site in USA*  
EUCLID – ticagrelor vs clopidogrel in PVD *high enrolling site in USA*  
ACCELERATE – evacetrapib in ACS *high enrolling site in USA*  
SIELLO - Biotronik lead evaluation clinical study *high enrolling site in USA*  
GRAND – TAK 875 in diabetic pts  
DECLARE TIMI 58 – Dapagliflozin in diabetic pts  
CIRT – Methotrexate in CAD pts  
GLORIA phase 1-3 – BI atrial fibrillation registry *high enrolling site in USA*  
CAMELLIA TIMI 61- lorcacerin-Belviq in high risk obese and overweight pts *high enrolling site*

## **Summary of Clinical Research Trials Participation (1994- present )**

ORBIT II- atrial fibrillation Registry *high enrolling site in USA*  
COMMANDER HF- Rivaroxaban in ischemic CHF  
TIGRIS- AZ ACS registry post PCI  
THEMIS- Ticagrelor in high risk diabetic pts  
PARAGON HF- ANRI in preserved EF heart failure  
CARMELINA- linagliptin in pts with diabetes, CAD and renal insufficiency  
GEMINI – Rivaroxaban in ACS  
VOYAGER- Rivaroxaban in PVD pts  
AUGUSTUS – apixaban vs warfarin post PCI in afib pts with DAPT or TAPT  
CADLAD – advanced analytics to assess for CAD  
HARMONY- albiglutide in diabetic pts to reduce CV events  
XL PAD- Vorapaxar vs. Placebo in PAD pts  
PARADISE MI – Entresto vs. Ramipril in AMI pts  
PROMINENT – Pemafibrate vs. Placebo in high TG diabetic pts  
CLEAR – Bempedoic acid vs Placebo in statin intolerant pts  
EMPEROR- empagliflozin in HFPEF pts  
DAPA-HF- dapagliflozin in HFREF pts  
ST JUDES BRADY MRI – Post approval MRI PM follow up  
GOULD- PCSK9 Registry  
LOWER- Juxtapid Registry  
CADFEM- advanced analytics to assess for CAD  
VESALIUS- alirocumab in CVD pts  
NODE 303- Etripamil for SVT prevention  
SELECT/SELECT LIFE- Semaglutide in overweight non diabetic pts  
ORION 4/HPS4- Inclisarin in CVD pts  
SURPASS- dulaglutide vs tirzepatide in type 2 diabetics  
AZALEA TIMI 71- rivaroxaban vs abeliceimab in high risk atrial fibrillation  
CARE HF- CHF registry to monitor hyperkalemia  
ZEUS- Ziltvekimab in CAD and CKD pts  
VICTOR MK1242-035 – Verciguat in stable HFrEF pts  
Amgen LPa surveillance study  
LIBREXIA- Milvexian Fx11a inhibitor vs apixaban in afib trial  
Oceanic AF- Asundexian Fx 11a inhibitor in afib trial  
SURMOUNT- tirzepatide obesity outcomes trial  
HERMES- Ziltvekimab in HFPEF pts  
BI CVOT SYNCHRONIZE– Survodutide GLP1/GCGR agonist in obesity outcomes trial  
LILAC- abeliceimab in pts not able to take OAC  
POETIC- registry of CVD pts and weight management  
PREVAIL- Obicetrapib in CVD pts with hyperlipidemia  
TANDEM- Obicetrapib in CVD pts or with familial hyperlipidemia  
EASI-HF- Preserved Vicadrost and Empagliflozin in HF  
EASI HF- Reduced Vicadrost and Empagliflozin in HF  
OCEAN (a) Outcomes- Olpasarin ( LPa) and CVD risk reduction  
OCEAN (a) Prevention- Olpasarin ( LPa) and CVD risk reduction  
PRECIDENTD- SGLT2 inhibitors vs GLP 1 agonists real world comparison  
PREVENT HF- Baxdrostat and Dapagliflozin to prevent HF in diabetics  
ROXI-ATLAS- REGN7508 and 9933 vs apixaban in atrial fibrillation  
ZENITH-Zelibesiran in hypertensives with CVD or high risk factors  
EASI PROTKT – Vicadrost/empagliflozin in Type 2 diabetics with high BP  
ROXI-EVEREST- REGN7508 vs apixaban in atrial fibrillation  
ROXI-INCLINE- REGN7508 and 9933 vs apixaban in atrial fibrillation pt not able to take OAC

POLARIS-amycrin in HFPEF patients  
AMBIENCE-Zenagantide to reduce MACE events in overweight and obese ASCVD pts

## ***Summary of Clinical Research Trials Participation (1994- present )***

### **Co-Investigator- USA**

Adenosine Nuclear Stress - role of exercise during adenosine infusion, helped design study  
FUSION II- outpt neseritide infusions for CHF  
Ranolazine Dosing Trial- inpt high dose ranolazine trial  
TOPCAT- aldactone in diastolic heart failure  
ROCKET AF – rivaroxaban in atrial fibrillation  
CARDIOMEMS- wireless PA sensor for CHF monitoring

### **Principal Site Investigator- Canada**

CARS- low dose ASA and warfarin in ACS, one of the top enrolling sites in North America  
ESSENCE- enoxaparin in ACS, one of the top enrolling sites in North America  
TRILOGY DR+- St Judes PM trial  
PROTECT- perindopril in CAD pts  
TIMI 11B- enoxaparin in ACS pts, one of the top enrolling sites in North America  
MIRACL ACS- atorvastatin in ACS pts, one of the top enrolling sites in North America  
OPUS-TIMI-16- sirofiban in ACS, one of the top enrolling sites in North America  
RASTAF- Medtronic PM trial  
PRINCESS- cerivastatin in ACS  
OPUS-Angiographic- sirofiban angiographic sub study  
Practice Patterns in Atrial Fib- Canadian atrial fib registry, was part of the steering committee  
OVERTURE- omapatrilat vs enalapril in CHF  
OCTAVE- omapatrilat in hypertension  
Tirofiban Evaluation Study- hospital based comparative trial vs eptifibitide  
CHARM- candesartan in CHF  
MERCURY II- high dose rosuvastatin in CAD pts  
INTERACT- enoxaparin in ACS, top enrolling site worldwide  
SPORTIF-V- ximelgatrobant vs warfarin in atrial fibrillation  
ADONIS- dronedarone in atrial fibrillation  
AF CHF- rate vs rhythm control in CHF pts with atrial fib  
OAT- open artery hypothesis trial

## **Summary of Clinical Research Trials Participation (1994- present )**

### **Co-Investigator- Canada**

GUSTO – tpa vs streptokinase, *one of the top enrolling sites in North America*  
CAMIAT- amiodarone post myocardial infarction  
HOPE- ramipril in stable CAD, *one of the top enrolling sites in North America*  
CAPRIE- clopidogrel in atherosclerotic disease, *one of the top enrolling sites in North America*  
C-TOPP- dual vs single chamber pacing, *one of the top enrolling sites in North America*  
GUSTO II & IIb- hirudin vs heparin in ACS  
GUSTO III- tpa vs reteplase  
ACHIEVE- acebutolol in CHF  
DIG- digoxin in CHF, *one of the top enrolling sites in North America*  
RESOLVD- candesartan in CHF  
SPICE- candesartan in CHF  
CTAF- anti arrhythmic therapy in atrial fibrillation  
CONVINCE- verapamil vs atenolol in CAD  
CARDIZEM CD- diltiazem effect on exercise tolerance  
ACTION- nifedipine XL in CAD pts  
ASSENT II- tenecteplase vs alteplase  
COPERNICUS-carvedilol in acutely decompensated CHF  
CORE- ReoRx infusion in ACS pts  
VALIANT- valsartan vs captopril post myocardial infarction  
CURE- carvedilol in acute coronary syndromes, *one of the top enrolling sites in North America*  
GUSTO IV-ACS- Reteplase in ACS  
GUSTO V- reteplase vs Reteplase in ACS  
HOPE 2- vitamin E vs placebo, *one of the top enrolling sites in North America*  
NICE-3- enoxaparin vs IIb/IIIa inhibitors in ACS  
PROVE-IT- atorvastatin vs pravastatin in ACS, *one of the top enrolling sites in North America*  
SYNERGY- enoxaparin vs IIb/IIIa inhibitors in ACS  
ON TARGET- telmisartan vs ramipril in CAD  
CAMELLIA TIMI 61- icosapent ethyl in high risk obese and overweight pts  
CIRT – Methotrexate in CAD pts  
DECLARE TIMI 58 – Dapagliflozin in diabetic pts  
SOCRATES Reduced- BAY1021189 oral sGC stimulator in HFrEF  
SOCRATES Preserved- BAY1021189 oral sGC stimulator in HFpEF  
REDUCE-IT- EPA ethyl esters in CAD and high risk diabetics – *high enrolling site*  
FOURIER- evolucumab in high risk vascular pts  
CASCADE/EMPA-REG– Empagliflozin to reduce CV events  
PEGASUS- Ticagrelor vs ASA post MI  
PARAMOUNT- LCZ696 in diastolic heart failure  
PALLAS- dronedarone in CHF patients  
GARFIELD- atrial fibrillation registry  
ATMOSPHERE- aliskiren in CHF pts  
HARMONY- albiglutide in diabetic pts to reduce CV events  
STRENGTH – EPA Omega 3 in CAD pts  
PROMINENT - Pemafibrate vs. Placebo in high TG diabetic pts  
SODIUM HF – dietary sodium in CHF pts  
VESALIUS- alirocumab in CVD pts  
AZ REALIZE K- SZK in hyperkalemic pts with CHF  
AZ MIRACLE- AZD9977 vs dapagliflozin in CHF pts with CKD  
EMPEROR – Preserved- Empagliflozin in HFpEF  
ARROWHEAD – AROAPOC3-2001 in severe hypertriglyceridemia

DELIVER- dapagliflozin in HFpEF pts  
FineArts- Finerenone in preserved EF  
OCEAN (a)- Olpasarin ( LPa) and CVD risk reduction  
POETIC- registry of CVD pts and weight management  
LIBREXIA- Milvexian Fx11a inhibitor vs apixaban in afib trial  
SEAFRONT-biobank analysis of blood coagulability in A-fib and arterial disease  
ZENITH-Zelibesiran in hypertensives with CVD or high risk factors

### ***Summary of Investigator-Initiated Research*** (1994- present )

- have designed and conducted multiple research studies that have focused on
  - access to care, wait times, resource utilization
  - acute coronary syndromes
  - health outcomes in Canada and USA
  - processes of care
  - heart disease in South Asians
  - disparities in care for visible minorities

**PLEASE SEE PUBLICATION LIST FOR FURTHER DETAILS**

### ***Summary of Other Research Activities*** (1994- present )

- consulted for Takeda – designing chronic angina trial (EXERT)
- consulted for Glock – designing cholesterol absorption trial (G-PUR)
- Steering Committee – SPRINT- AF study, CCRN, Canada
- Steering Committee – CLASS ACT study, CCRN, Canada
- Steering Committee – REACT study, CCRN, Canada
- Journal Reviewer – American Heart Journal
- Journal Reviewer – American Journal of Cardiology
- Journal Reviewer – Canadian Medical Association Journal
- Journal Reviewer – Journal of The American Medical Association
- Abstract Reviewer – Canadian Cardiovascular Society meeting
- Abstract Reviewer – American Heart Association meeting

## **Summary of Honors, Awards, Grants**

**(1994 - present)**

**1996-** \$ 4000 Physicians Services Inc.(PSI) Foundation Grant for the Effect of Early Ambulation on Hematoma Formation and Vascular Complications Study

**1998-** \$ 8000 Bristol-Myers-Squibb Research Grant to evaluate the presentation of Myocardial Infarctions in South Asians versus European Canadians

**1999-** \$ 12000 Bristol-Myers Squibb Research Grant – continue to evaluate the presentation of Myocardial Infarctions in South Asians versus European Canadians

**1999-** \$ 12000 Parke-Davis Research Grant – to evaluate the compliance of South Asians versus European Canadians patients with a diagnosis of CAD in the office setting

**1999-** HCPRA 2<sup>nd</sup> place award for Excellence in Health Care Communication, Special Purpose Publication-General Category

**2000-** \$ 12000 Parke-Davis Research Grant – to evaluate the burden of CAD in South Asians vs European Canadians presenting to the cath lab

**2000-** \$ 12000 Roche Research Grant – to evaluate the presentation of South Asians versus European Canadians patients with CHF in the hospital

**2000-** \$ 12000 Key-Schering Research Grant – to evaluate the outcomes and compliance of South Asians versus European Canadians patients participating in cardiac rehabilitation

**2001-** Awarded plaque of recognition for 6 years of contribution to the GTACC organization as the founding chair and then executive committee member

**2001-** Presented letter of appreciation from the Prime Minister of Canada for volunteer efforts in conjunction with the Canadian Cardiovascular Society

**2002-** Awarded plaque from CCC advisory group “in appreciation of your guidance and support for the cardiac care of the people in our community”

**2002-** Awarded plaque from Rouge Valley Health System Foundation acknowledging “outstanding commitment and generosity of donations, time, and leadership” to RVHS Cardiac Care Program

**2002-** Awarded plaque from RVHS Cardiologists - “in recognition of outstanding clinical skills and leadership in promoting high quality care” to RVHS

**2002-** Awarded plaque from Canadian Cardiovascular Society – in appreciation of contributions as Secretary 2000-2002

**2007-** Awarded plaque from Northside Hospital – in appreciation of contributions as Section Chair, Cardiology

**2010-** Awarded \$173,000 investigator-initiated research grant from Gilead Sciences to look at the effect of ranolazine on CAD pts with metabolic syndrome and varying ethnicities

**2010-** Awarded “Distinguished Service Award” – from American College of Cardiology- GA Chapter for work as CME chair over past 6 years



**2010-** Awarded through CCRN and Dr M Gupta investigator initiated grant from Astra Zeneca of \$3,664,353 for the PARADIGM study Primary Care Audit of Global Risk Management

**2011-** Awarded \$49,170 investigator-initiated research grant from Medtronic to look at the differential ICD utilization rates among various ethnic pts with advanced heart failure

**2012-** Awarded \$53,000 investigator-initiated research grant from Astellas to look at the Appropriate Use Criteria for outpt nuclear studies amongst physicians, gender and ethnicity

**2012-** Awarded through CCRN and Dr M Gupta investigator initiated grant of \$2,845,668 from Bayer for the SPRINT-AF study Stroke Prevention in atrial fibrillation-A Prospective Canadian Registry

**2014-** Awarded through CCRN and Dr M Gupta investigator initiated grant of \$600,783 from Valeant for CLASS-ACT Study Colesevelam, Lipids and Sugars, South Asian Canadian Trial

**2016-** Awarded through CCRN and Dr M Gupta investigator initiated grant of \$2,500,000 from Sanofi-Aventis REACT Study - Relating Evidence to Achieving Cholesterol Targets Trial

**PEER-REVIEWED ARTICLES**

1. **Singh N**, Thomson L, Goldstein MB, Langer A. ST Segment Shift in Hemodialysis Patients. *Journal of Ambulatory Monitoring* 1993;6; 155-162.
2. **Singh N**, Langer A, Freeman MR, Goldstein MB. Myocardial Alterations during Hemodialysis; Insights from New Noninvasive Technology. *American Journal of Nephrology*, 1994;14:173-181
3. Langer A, **Singh N**, Freeman MR, Tibshirani R, Armstrong PW. Detection of silent ischemia adds to prognostic value of coronary anatomy and left ventricular function in predicting outcome in patients with unstable angina. *Canadian Journal of Cardiology*, 1995 II:2; 117-122.
4. **Singh N**, Langer A. Current status of silent myocardial ischemia. *Canadian Journal of Cardiology*, 1995 II: 4; 286-289.
5. **Singh N**, Mironov D, Goodman S, Morgan CD, Langer A. Treatment of silent ischemia in unstable angina: A randomized comparison of sustained-release verapamil versus metoprolol. *Clinical Cardiology*, 1995; 18: 653-658.
6. **Singh N**, Daly PA, Gemmell CH, Yeo EL. Assessment of platelet activation in unstable angina: Value of microparticle generation measurements using flow cytometry. *Canadian Journal of Cardiology*, 1995; 11 (11): 1015-1021.
7. **Singh N**, Mironov D, Ross AM, Armstrong PW, Langer A. Heart rate variability assessment early after acute myocardial infarction: Pathophysiologic and prognostic correlates. *Circulation*, 1996; 93:1388-1395.
8. **Singh N**, Kuganesan K, Goode E, Ricci AJ. on behalf of the Cardiac Care Program. The Effect of Early Ambulation on Hematoma Formation and Vascular Complications Following 7 French Diagnostic Cardiac Catheterization. *Canadian Journal of Cardiology* 1998; 14(10):1223-1227.
9. **Singh N**, Gupta M, Fell D, Gangbar E. Impact and Inequity of inpatient waiting times for advanced cardiovascular services in community hospitals across the Greater Toronto Area. *Canadian Journal of Cardiology* 1999 ;15(7):777-782.
10. Gupta M, Doobay A , **Singh N**, Raja F, Mawji F, Karvetian A, Anand S, Yusuf S. A comparison of risk factors for and prognosis after acute myocardial infarction in South Asians and European Canadians. *Can Med Assoc Journal* 2002;166(6),717-722
11. Gillis AM, Philippon F, Cassidy MR, **Singh N**, Dorian P, Love BA, Kerr. Guidelines for implantable cardioverter defibrillator follow-up in Canada: A consensus statement of the Canadian Working Group on Cardiac Pacing. *Canadian Journal of Cardiology* 2002; 19(1):21-28.
12. Ross H, Hendry P, Dipchand A, Giannetti N, Hirsch G, Issac D, **Singh N**, West L, White M. 2001 Canadian Cardiovascular Society Consensus Conference on Cardiac Transplantation. *Canadian Journal of Cardiology* 2003; 19(6):620-635.

13. **Singh N**, Gupta M. Clinical Characteristics of South Asian patients hospitalized with heart failure. *Ethnicity and Disease*. 2005;15(4):615-619
14. Gupta M, **Singh N**, Verma S. South Asians and Cardiovascular Risk. What Clinicians Should Know. *Circulation*. 2006: 113:924-92
15. Banerjee A, Gupta M, **Singh N**. Patient Characteristics, Compliance and Exercise Outcomes of South Asians Enrolled in Cardiac Rehabilitation. *J Cardiopulmonary Rehabilitation and Prevention* 2007;27, 212-218.
16. Gupta M, **Singh N**, Tsigoulis M, Kajil M, Hirjikaka S, Quan A, Teoh H, Verma S Perceptions of Canadian Primary Care Physician Towards Cardiovascular Risk Assessment and Lipid Management *Canadian Journal of Cardiology* 2012;28, 14-19
17. Gupta M. **Singh N**, Impactful Clinical Trials of 2012: What Clinicians Should Know. *Canadian Journal of Cardiology* 29(2013)747-750
18. Abi-Samra FM, **Singh N**, Assi NA, Rosin BL, Dwyer JV, Miller CD for the CLEAR Investigators. Effect of Rate-Adaptive Pacing on Performance and Physiological Parameters during Activities of Daily Living: Results from the CLEAR (Cynos Responds with Physiological Rate Changes during Daily Activities) Study *Europace* 2013 Jun;15(6):849-56
19. Gupta M , Ha A, Cox J, Dorian P, Fournier C, Gladstone DJ, Lockwood E, Mancini J, Saldanha C, Shuaib A, **Singh N**, Kajil M , Tsigoulis M, Verma S . Patterns of oral anticoagulant use for stroke prevention in contemporary Canadian atrial fibrillation practice -insights from the Stroke Prevention and Rhythm Interventions in Atrial Fibrillation (SPRINT-AF) registry *Canadian Journal of Cardiology*; May 03, 2015, Vol32(2), 204-210
20. Gupta M, Szmitko PE, **Singh N**, Tsigoulas M, Kajil M, Stone J. Management and control of Uncomplicated Hypertension in Canada: Insight from the Primary Care Audit of Global Risk Management (PARADIGM) Study *Canadian Journal of Cardiology* 31(2015)664-670
21. Law TK, Yan AT, Gupta A, Kajil M, Tsigoulis M, **Singh N**, Verma S, Gupta M. Primary Prevention of Cardiovascular Disease: Global Cardiovascular Risk Assessment and Management in Clinical Practice. *European Heart Journal –Quality of Care and Clinical Outcomes*, Volume 1, Issue 1, July 2015, 31-36
22. Gupta M, Szmitko P, **Singh N**, Tsigoulis M, Kajil M, Stone J. Management and Control of Uncomplicated Hypertension in Canada: Insight from the Primary Care Audit Of Global Risk Management (PARADIGM) Study; *Canadian Journal of Cardiology*; May 2015, Vol. 31(5), 664-670
23. Ha A, **Singh N**, Cox J, Mancini J, Dorian P, Fournier C, Gladstone DJ, Lockwood E, Shuaib A, Kajil M, Tsigoulis M, Gupta M. Oral Anticoagulation for Stroke Prevention in Canadian Practice: Stroke Prevention and Rhythm Interventions in Atrial Fibrillation (SPRINT-AF) Registry *Canadian Journal of Cardiology* 32(2016)204-210

24. Gupta M, Kajil M, Tsigoulis M, Verma S, **Singh N**. Audit of Cardiovascular Risk Assessment and Lipid Management in Canadian Primary Care Physicians. *Curr Res Cardiol* 2016;3(2):33-37

25. **Singh N**, Gupta M. Impactful Clinical Trials of 2015: What Clinicians Should Know. *Canadian Journal of Cardiology* 32(2016)1038 e17-e20

26. Gupta M, Paul S, Kajil M, Ostrovski L, Tsigoulis M, Verma S, **Singh N**. Acetylsalicylic acid use in primary prevention in Canada: Insight from the primary care audit of global risk management (PARADIGM) study. *Curr Res Cardiol*. 2016,3(3):67-70

27. Stuckey T, Gammon R, Goswami R, Depta J, Steuter J, Meine F, Roberts M, **Singh N**, Ramchandani S, Burton T, Grouchy P, Khosousi A, Shadforth I, Sanders W. Cardiac Phase Space Tomography: A novel method of assessing coronary artery disease utilizing machine learning *PLoS ONE* 2018 13(8): e0198603.  
<https://doi.org/10.1371/journal.pone.0198603>

28. Alothman L, Zawadka M, Aljenedil S, Kajil M, Bewick D, Gaudet D, Hegele R, Lonn E, Ngui D, Ruel I, Tsigoulis M, **Singh N**, Genest J, Gupta M. Prediction of Familial Hypercholesterolemia in Patients at High Atherosclerotic Cardiovascular Disease Risk Using a Recently Validated Algorithm. *Canadian Journal of Cardiology Volume 1, issue 4, July 2019, Pages 190-197*.

29. Ridker P, Everett B, Pradhan A, MacFadyen J, Solomon D, Zaharris E, Mam V, Hasan A, Rosenberg Y, Iturriaga E, Gupta M, Tsigoulis M, Verma S, Clearfield M, Libby P, Goldhaber S, Seagle R, Ofori C, Saklayen M, Butman S, **Singh N**, Le May M, Bertrand O, Johnston J, Paynter NP, Glynn RJ. Low-dose methotrexate for the prevention of atherosclerotic events. *N Engl J Med* 2019; 380:752-762

30. Alothman L, Zawadka M, Aljenedil S, Kajil M, Bewick D, Guadet D, Hegele R, Lonn E, Ngui D, Ruel I, Tsigoulis M, **Singh N**, Genest J, Gupta M. Prediction of Familial Hypercholesterolemia in Patients at High Atherosclerotic Cardiovascular Disease Risk Using a Recently Validated Algorithm *CJC Open* 1 (2019) 190-197

31. James E Ip Hanh Bui, A John Camm, Benoit Coutu, Peter A Noseworthy, Maria Leonor Parody, Samuel F Sears, **Narendra Singh**, Juan Agudelo Uribe, John Vyselaar, Sarah Omodele, Silvia Shardonofsky, David B Bharucha, Bruce Stambler, Rationale and design of the NODE-303 study: Evaluating the safety of symptom-prompted, self-administered etipamil for paroxysmal supraventricular tachycardia episodes in real-world settings *American Heart Journal*, January 2024.

32. Ip J, Couto B, Noseworthy P, Parody M, Rafii F, Sears S, **Singh N**, Stambler B, Bharucha D, Camm J. Research Letter- Etipamil Nasal Spray for Recurrent Paroxysmal Supraventricular Tachycardia Conversion, *JACC*, vol 83, no 20, 2024

33. Ip JE, Couto B, Ip JH, Noseworthy P, Parody M, Rafii F, Sears S, **Singh N**, Stambler B, Tahikheli N, Agudelo-Uribe J, Hu D, Shardonofsky S, Sheikh M, Holz A, Bharucha D, Camm J. Etipamil Nasal Spray for Recurrent Paroxysmal Supraventricular Tachycardia Conversion: Results from the NODE-303 Open Label Study *J Card Electrophysiology* Aug 2025

34. Ip JE, Couto B, Ip JH, Noseworthy P, Parody M, Rafii F, Sears S, **Singh N**, Stambler B, Tahikheli N, Agudelo-Urbe J, Hu D, Shardonofsky S, Sheikh M, Holz A, Bharucha D, Camm J. Minimal Blood Pressure Effects of Intranasal Etripamil for Paroxysmal Supraventricular Tachycardia, *JACC:Advances* May 2026
35. Todd Villines, Narendra Singh, Anne- Sophie Lacharite, Jonathan Hsu, Farhad Rafii, and Alexander Blood PSVT Treatment Evaluating the Evidence for Established and Newly Approved Options, *JACC Advances* , *In press*

### **PUBLISHED ABSTRACTS**

1. **Singh N**, Thomson L, Goldstein MB, Langer A. Detection of ST Segment Shift in Hemodialysis Patients; A Possible Link to High Cardiovascular Mortality in End-Stage Renal Disease.  
*Journal of the American College of Cardiology* 1992; 19(3): 390A
2. **Singh N**, Langer A, Hsia T, Thomson L, Goldstein MB, Freeman MR. On- Line Assessment of Left Ventricular Function in End Stage Renal Disease: New Evidence for Myocardial Ischemia During Hemodialysis.  
*Canadian Journal of Cardiology* 1992;8(Suppl. B): 81B
3. **Singh N**, Langer A, Freeman MR, Goldstein MB. Perfusion Defects in Hemodialysis Patients: Correlation with on- line ST-segment Analysis.  
*Canadian Journal of Cardiology* 1993; 9(Suppl. E): 127E
4. **Singh N**, Daly PA, Gemell C, Yeo EL. Platelet Activation in Acute Coronary Syndromes: Assessment Using Dual Label Flow Cytometry.  
*Canadian Journal of Cardiology* 1993; 9(Suppl. E): 74E.  
*Circulation* 1993; 88 (suppl): I-516
5. **Singh N**, Cox JL, Naylor CD, Brophy J, Langer A. Regional Variations in Resource Utilization and Outcomes Post MI  
*Canadian Journal of Cardiology* 1994; 10(Suppl. C): 87C.
6. **Singh N**, Cox J, Naylor CD, Brophy J, Armstrong PW, Langer A. Outcomes of Acute MI Presenting at University vs Community Hospitals: The GUSTO Canadian Experience.  
*Canadian Journal of Cardiology* 1994; 10(Suppl. C): 98C.  
*Circulation* 1994; 90 (suppl): I-325
7. **Singh N**, Mironov D, Goodman S, Morgan CD, Langer A. Treatment of Silent Ischemia in Unstable Angina: A Randomized Comparison of Isoptin SR Versus Metoprolol.  
*Canadian Journal of Cardiology* 1994; 10(Suppl. C): 130C.  
*Journal of the American College of Cardiology* 1995; 25 Suppl A: 88A
8. **Singh N**, Mironov D, Ross AM, Armstrong PW, Langer A. Heart-Rate Variability During the First 48 Hours Post Infarction: GUSTO Angiographic and Clinical Correlates.  
*Canadian Journal of Cardiology* 1994; 10(Suppl. C): 111C.  
*Circulation* 1994; 90 (suppl): I-274.

9. **Singh N**, Ricci AJ for the Cardiac Care Committee, Centenary Health Centre. An Integrated Approach to Optimizing Effectiveness of Acute Myocardial Infarction (AMI) Management in the Community.  
*Clin Invest Med* 1996; 19(4); S7.
10. **Singh N**, Kuganesan K, Goode E, on behalf of the Cardiac Care Program. The Effect of Early Ambulation on Hematoma Formation and Vascular Complications Following 7 French Diagnostic Cardiac Catheterization.  
*Canadian Journal of Cardiology* 1997; 13 (suppl C):104C.
11. Gupta M, **Singh N**, Gangbar E, Fell D. Inequity of Access to Inpatient Coronary Angiography in Greater Toronto Area (GTA) Community Hospitals  
*Canadian Journal of Cardiology* 1998; 14 (suppl F):132F
12. **Singh N**, Gupta M, Gangbar E, Fell D. Impact of In-Patient Waiting Times for Advanced Cardiovascular (CV) Services in Greater Toronto Area (GTA) Community Hospitals  
*Canadian Journal of Cardiology* 1998; 14(suppl F):115F
13. Gupta M, **Singh N**, Raja F, Mawji F, Doobay A, Anand S, Yusuf S. A comparison of risk factors for and prognosis after acute myocardial infarction in South Asians and European Canadians.  
*Canadian Journal of Cardiology* 1999; 15(suppl D):105D
14. **Singh N**, Gupta M. Physician Resources and Threshold Caps Key Determinants of Prolonged Waits to see Cardiologists in Greater Toronto Area (GTA).  
*Canadian Journal of Cardiology* 1999; 15(suppl D):171D
15. **Singh N**, Gupta M. Temporal trends in in-patient waiting times and outcomes for advanced cardiovascular services in Greater Toronto Area (GTA) community hospitals.  
*Canadian Journal of Cardiology* 2000; 16(suppl F):148F
16. **Singh N**, Gupta M. Jain A, Halperin D, Borts D. Differences in presentation and 1 yr outcomes in coronary artery disease(CAD) patients of South asian vs European Ethnicity Treated in an Outpatient Cardiology Practice  
*Journal of the American College of Cardiology* 2001;37(suppl D):171D
17. **Singh N**, Gupta M, Biswas T, Nguyen QM, Ali K. Impact on South Asian Ethnicity On Presentation and Outcomes with Hospitalization for Congestive Heart Failure.  
*Canadian Journal of Cardiology* 2001;17(suppl C):60C.  
*Journal of the American College of Cardiology* 2001; 39 (suppl A): 193A
18. Gupta M, **Singh N**, Warsi M, Reiter N, Ali K. Canadian South Asians have more Severe Angiographic Coronary Disease than European Canadians Despite having fewer risk factors  
*Canadian Journal of Cardiology* 2001;17(suppl C):68C
19. Gupta M, **Singh N**, Canadian Women of South Asians Origin are twice as likely to have Left Main Or 3-Vessel Coronary Disease as Women of European Origin.  
*Canadian Journal of Cardiology* 2001;17(suppl C):71C
20. **Singh N**, Gupta M, Janmohamed A, Dorian P. Who needs and Implantable Defibrillator (ICD), Considerable Inconsistency among Cardiologists despite National Consensus Guidelines,  
*Journal of the American College of Cardiology* 2002; 39 (suppl B): 212B

21. **Singh N**, Gupta M, Ricci AJ, Bopari S, Malik K, Significant Differences in Risk Factors, Compliance, and Exercise Outcomes Identified In South Asian Cardiac Rehabilitation Patients  
*Canadian Journal of Cardiology* 2002; 18(supp B):220B
22. **Singh N**, Santa M, Van Crisco L, Significant time delays in transfer for primary PCI versus on-site thrombolysis for STEMI patients in an urban American community hospital.  
*Canadian Journal of Cardiology* 2004;20 (supp D):123D
23. **Singh N**, Prabakaran K, Crisco LV, Baig F, McCallister T. Low level exercise with adenosine infusion improves image quality, symptom tolerance and arrhythmias during nuclear myocardial perfusion studies  
*Canadian Journal of Cardiology* 2005
24. Prabakaran K, **Singh N**. Effect of Low level Exercise with Adenosine on Septal Perfusion in LBBB.  
*Journal of Nuclear Medicine* 2006; 47:5 (May suppl):535P
25. Gupta M, **Singh N**, Teoh H, Yi Q, Strauss M, Tsigoulis M, Verma S, Eikelboom J. Fibrinolytic Function In South Asians And Europeans With Coronary Heart Disease: Insights From The Practice Registry  
*Canadian Journal of Cardiology* 2010
26. **Singh N**, Kaleka P, Patel P, Patel R, Balk M. Office Based Measurement Of Waist And Hip Circumference By Cardiologists Does Not Translate Into Improved Subsequent Measurements Or Reduced Weight  
*Journal of the American College of Cardiology* April 2011
27. Vaccari D, Alvarenga C, Jesus I, Layher J, Takahashi A, **Singh N**, Siot P, Elkaim JP. Results of a large prospective registry of pacemaker patients programmed with minimized ventricular pacing algorithm:even minimized, ventricular pacing remains a significant predictor of AF occurrence.  
*Europace* 2011
28. **Singh N**, Kaleka P, Chandra S, Song D, Yan L, Suh D, Dorsey A, Ramamurthy S Ethnic Differences in Patient Characteristics, But Not Implantable Cardioverter-Defibrillator (ICD) Utilization Rates for Primary Prevention of Sudden Cardiac Death (SCD) *Canadian Journal of Cardiology* 2011, *Circulation* 2011
29. **Singh N**, Hall E, Lucas E, Chandra S, Song D, Yan L, Suh D, Dorsey A, Ramamurthy S Potential Primary Prevention Implantable Cardioverter-Defibrillator (ICD) Patients Lack Understanding, Want More Information and are Willing to Reconsider Implant Refusal.  
*Canadian Journal of Cardiology* Oct 2012, *Circulation* 2012
30. Saha D, Tsigoulis M, Verma S, Singh N, Gupta A, Gupta M. Prevalence of Risk Factors and Occult Coronary Disease in South Asians Referred to a Specialized Risk Assessment Clinic *Canadian Journal of Cardiology* Oct 2012
31. Gupta, A., Kajil, M., **Singh, N.**, Tsigoulis, M. Verma, S., Gupta, M. Variability in traditional and novel cardiovascular risk factors by ethnic origin: Insights from the primary care audit of global risk management (PARADIGM) study. *AHA* 2012

32. **Singh N**, Amin A, Chandra S, Song D, Yan L, Suh D Significant Difference in Appropriate Use Criteria (AUC) Score for Outpatient SPECT Myocardial Perfusion Imaging (MPI) based on Age, Gender, Ethnicity, Site and Ordering Physician. (*JACC 2013*)
33. Gupta M, Kajil M, Tsigoulis M, **Singh N**, Verma S. – Prevalence of Chronic Kidney Disease (CKD) in Non-Diabetic Middle-Aged Adults: Insight from the PARADIGM Study *CCS 2013*
34. Gupta M, Kajil M, Tsigoulis M, Bansal A, Hirjikaka S, **Singh N**, Verma S. – Adherence to Evidence based medications in South Asian and white Caucasian patients with coronary heart disease: Insight from the PRACTICE Study *CCS 2013*
35. **Singh N**, Premji S, Chandra S, Song D, Yan L, Suh D. Suboptimal Time in Therapeutic Range (TTR) for International Normalized Ratio (INR) measurements observed in an outpatient cardiology clinic : Impact of Gender, Ethnicity, Disease Etiology, CHADSVasc score, Physicians and Clinic site. *Canadian Journal of Cardiology Oct 2013*
36. **Singh N**, MCMunn J, Chandra S, Song D, Yan L, Suh D. Multiple factors may contribute to physician variability in Appropriate Use Criteria (AUC) scores for Myocardial Perfusion imaging (MPI) *Canadian Journal of Cardiology Oct 2013*
37. Gupta M, Ha A, Cox J, Dorian P, Fournier C, Gladstone DJ, Lockwood E, Mancini J, Saldanha C, Shuaib A, **Singh N**, Kajil M, Tsigoulis M, Verma S. Factors Associated with New Oral Anticoagulant versus Vitamin K Antagonist Use in a Contemporary, National, Real-World Observational Registry: Insights from the Stroke Prevention and Rhythm Interventions in Atrial Fibrillation (SPRINT-AF) Registry (*ACC 2014*)
38. Gupta M, Ha A, Cox J, Dorian P, Fournier C, Gladstone DJ, Lockwood E, Mancini J, Saldanha C, Shuaib A, **Singh N**, Kajil M, Tsigoulis M, Verma S. Disagreement between Physician-Reported and Scoring System-Based Stroke and Bleeding Risks in Patients with Atrial Fibrillation: Insights from the Stroke Prevention and Rhythm Interventions in Atrial Fibrillation (SPRINT-AF) Registry (*ACC 2014*)
39. Ha AC, **Singh N**, Cox JL, Dorian P, Fournier C, Mancini GBJ, Shuaib A, Kajil M, Tsigoulis M, Gupta MK. Is Accurate Stroke Risk assessment with CHADS<sub>2</sub> Necessary in Managing Patients with Atrial Fibrillation? Insights from the Stroke Prevention and Rhythm Interventions in Atrial Fibrillation (SPRINT-AF) Registry (*CCS and AHA 2014*)
40. Gupta MK, **Singh N**, Cox JL, Dorian P, Fournier C, Mancini GBJ, Shuaib A, Kajil M, Tsigoulis M, Ha AC. High Rates of antiplatelet Use in Atrial Fibrillation Patients Treated With Oral Anticoagulation: Insights from the Stroke Prevention and Rhythm Interventions in Atrial Fibrillation (SPRINT-AF) Registry (*CCS and AHA 2014*)
41. **Singh N**, Dubal P, Turner K, Adams H, Chandra S, Song D, Yan L, Suh D. Ranolazine, Ethnicity and the metabolic syndrome (REMS) study: A pilot study showing the differential effects amongst Caucasians, African Americans, and Asians in exercise tolerance time (ETT) and glycemic control but not angina scores. (*ADA and ESC 2014*)
42. Law, T.K., Yan, A.T., Tsigoulis, M., Kajil, M., Verma, S., Singh, N., Gupta, M. Gender-Related Differences in Cardiovascular Risk Assessment and Management in Primary Care: Insights from the Primary Care Audit of Global Risk Management (PARADIGM) Study *CCC 2014*



43. Ha, A., **Singh, N.**, Tsigoulis, M., Kajil, M., Verma, S., Cox, J., Dorian, P., Fournier, C., Gladstone, D., Lockwood, E., Mancini G., Saldanha, C., Shuaib, A., Tsigoulis, M., Gupta, M. The influence of stroke and bleeding risk on oral anticoagulant use for stroke prevention in patients with atrial fibrillation: Insights from the Stroke Prevention and Rhythm Interventions in Atrial Fibrillation (SPRINT-AF) registry *CCC 2014*
44. **Singh N**, Dubal P, Jain N, Chandra S, Song D, Yan L , Suh D. Suboptimal Adherence to Evidence Based Coronary Artery Disease (CAD) Therapy: Impact of Gender, Ethnicity, Prescribing Physician and Drug Intolerance. *Canadian Journal of Cardiology 2014*
45. Gupta MK, **Singh N**, Tsigoulis M, Kajil M, Cox JL, Dorian P, Mancini GBJ, Ha AC . Underuse of Full Dose Factor Xa Inhibition in Atrial Fibrillation: Insights from the Stroke Prevention and Rhythm Interventions in Atrial Fibrillation (SPRINT-AF) Registry (*ACC 2015*)
46. Kaushal A, Kajil M, Tsigoulis M, Gill S, **Singh N**, Yan AT, Gupta M. The Risk of Obstructive Sleep Apnea in a healthy, middle aged North American population: Insights from the PARADIGM study. *Canadian Journal of Cardiology 2015*
47. Foltz T, **Singh N**, S Chandra S, Song D, Yan L , Suh D. Higher Chadsvasc Scores But Similar Complication And Mortality Rates In Women With Atrial Fibrillation Over 1 Year In An Outpatient Cardiology Setting *AHA 2016*
48. Gupta M, Kajil M, Tsigoulis M, Dhillon P, Cox J, Dorian P, Fournier C, Gladstone D, Lockwood E, Mancini J, Shuaib A, **Singh N**, Ha A. Sex Differences In Stroke Risk Profile, Stroke Prevention Therapy Use And Treatment Satisfaction In A Contemporary Cohort Of Patients With Atrial Fibrillation: Insights From SPRINT-AF *AHA 2016*
49. Ha A, Kajil M, Tsigoulis M, Dhillon P, Cox J, Dorian P, Fournier C, Gladstone D, Lockwood E, Mancini JB, Shuaib A, **Singh N**, Gupta M. Patterns of antithrombotic use in relation to the CHA2DS2-VASC and the CHADS2-65 stroke risk score in contemporary practice: Insights from a prospective Canadian atrial fibrillation (SPRINT-AF) registry. *CCC 2016*
50. Shuaib A, Ha A, Kajil M, Tsigoulis M, Cox J, Dorian P, Fournier C, Gladstone D, Lockwood E, Mancini J, **Singh N**, Gupta M . A cross Canada assessment of management of patients with a history of TIA or stroke related to atrial fibrillation. Insights from SPRINT-AF registry *CSA 2016*
51. Ha A, Wu Y, Kajil M, Tsigoulis M, Dhillon P, Cox J, Dorian P, Fournier C, Gladstone D, Lockwood E, Mancini J, Shuaib A, **Singh N**, Gupta M. Concomitant use of antiplatelet and oral anticoagulation among patients with atrial fibrillation: Insights From SPRINT-AF *ACC 2017*
52. Crawford S, Burton T, Sander Jr WE. Coronary Artery Disease Learning and Algorithm Development Study (CADLAD): Early Analysis of Ejection Fraction Evaluation. *ACC 2017*
53. Foltz T, **Singh N**, S Chandra S, Song D, Yan L , Suh D. Marked Physician Variability in Oral Anticoagulant Treatment Choices Reflect Significant Differences in Atrial Fibrillation Patient Characteristics *ACC 2017*
54. Gupta M, Labos C, Kajil M, Tsigoulis M, Cox J, Dorian P, Mancini G.B.J, Fournier C, Gladstone D, Lockwood E, Shuaib A, **Singh N**, Ha A. Which factors influence the choice

of a nonvitamin K oral anticoagulant over warfarin for stroke prevention among atrial fibrillation patients? Insights from the prospective SPRINTAF registry *ESC 2017*

55. Jayaprakash H.K, Labos C, Shuaib A, Kajil A, Tsigoulis M, Cox J, Dorian P, Mancini G.B.J, Fournier C, Gladstone D, Lockwood E, **Singh N**, Ha A, Gupta M. Do atrial fibrillation patients with history of cerebrovascular accidents receive guideline concordant stroke preventive therapies? Insights from the prospective SPRINTAF registry *ESC 2017*
56. Ha A, Kajil M, Tsigoulis M, Labos C, Cox J, Dorian P, Mancini G.B.J, Fournier C, Gladstone D, Lockwood E, Shuaib A, **Singh N**, Gupta M. Antithrombotic use amongst patients at low stroke risk as defined by the CHA2DS2VASc score: Insight from the prospective SPRINTAF registry *ESC 2017*
57. Labos C, Ha A, Kajil M, Tsigoulis M, Cox J, Dorian P, Mancini J, Gladstone D, Lockwood E, Shuaib A, Sikri H, **Singh N**, Gupta M. Appropriateness of non-vitamin K oral anticoagulant dosing among Canadian atrial fibrillation patients *CCC 2017*
58. Gupta M, Ha A, Kajil M, Tsigoulis M, Cox J, Dorian P, Mancini J, Gladstone D, Lockwood E, Shuaib A, **Singh N**, Labos C. Adequacy of hypertension control among patients with atrial fibrillation at high cardiovascular risk: Insights from a Canadian prospective registry *AHA 2017*
59. Labos C, Ha A, Kajil M, Tsigouls M, Cox J, Dorian P, Mancini J, Gladstone D, Lockwood E, Shuaib A, Sikri H, **Singh N**, Gupta M. Rates and patterns of inappropriate dosing for non-vitamin K oral anticoagulant among Canadian atrial fibrillation patients: Insights from a prospective registry *AHA 2017*
60. Stuckey T, **Singh N**, Goswami R, Depta J, Gammon R, Roberts M, Steuter J, Gupta S, Sanders W JR. Assessing CAD by Cardiac Phase Tomography Using Machined Learned Algorithms in Obese and Elderly *TCT 2017*
61. Stuckey T, **Singh N**, Goswami R, Depta J, Gammon R, Roberts M, Steuter J, Gupta S, Sanders W JR. Gender based Assessment of CAD by Cardiac Phase Tomography Using Machine-Learned Algorithms *TCT 2017*
62. Ha A, Labos C, Kajil M, Tsigoulis M, Cox J, Dorian P, Mancini G.B, Gladstone D, Lockwood E, Shuaib A, Chan W, **Singh N**, Gupta M. What factors influence the choice of Apixaban, Rivaroxaban, or Dabigatran for stroke prevention among atrial fibrillation. *ACC 2018*
63. Labos C, Ha A, Dorian P, Tsigoulis M, Kajil M, Cox J, Mancini G, Gladstone D, Lockwood E, Shuaib A, **Singh N**, Gupta M. Persistence of oral antigoagulent use among Canadian atrial fibrillation patients: One-year results from the prospective SPRINT-AF registry *CCC 2018*
64. Lonn E, Ngui D, Ruel I, **Singh N**, Genest J. The high prevalence of familial hypercholesterolemia in a population of ASCVD patients with LDL-C above target: an analysis from the REACT registry *CCC 2018*
65. **Singh N**, Premji S, Ramakrishnan D. Significant underutilization of angiotensin receptor neprolysin inhibitor (ARNI) and other evidence-based heart failure (HF) therapies in an outpatient clinic setting. *ESC HF 2019*

66. Ha A, Labos C, Dorian P, Mancini J, Cox J, Gladstone D, Lockwood E, **Singh N**, Shuaib A, Padarath M, Gupta M. Factors Associated with Changes With Impaired Quality of Life Among Atrial Fibrillation Patients in Real-world Clinical Practice: Insights From the Prospective Canadian SPRINT-AF Registry *AHA 2019 CCC 2019*
67. JE Ip, B. Coutu, JH Ip, P Noseworthy, ML Parody, F Rafii, S Sears, **N Singh**, B Stambler, N Tahirkheli, JAgudelo, S Omodele, S Shardonofsky, D Bharucha, AJ Camm. Multi-Center, Open-label study of the Efficacy and Safety of Etripamil Nasal Spray Self-Administers for Multiple Episodes of Symptomatic Supraventricular Tachycardia Without Supervision -Phase 3, NODE-303 ACC Atlanta 2024
68. JE Ip, B. Coutu, JH Ip, P Noseworthy, ML Parody, F Rafii, S Sears, **N Singh**, B Stambler, N Tahirkheli, JAgudelo, S Omodele, S Shardonofsky, D Bharucha, AJ Camm. Analysis of Healthcare Resource Utilization in the NODE-303 Clinical Trial to Terminate Paroxysmal Supraventricular Tachycardia Episodes *ISPOR 2024*
69. Nihar R Desai, James E Ip, Derek Hu, Peter A Noseworthy, Maria L Parody, Sean D Pokorney, Farhad Rafii, **Narendra Singh**, Bruce S Stambler, Silvia Shardonofsky, David B Bharucha, A. John Camm. Frequency and Patterns of PSVT episodes among Etripamil Users: Analysis of the NODE-303 Open Label Trial AHA Chicago 2024
70. James Edmund Ip, Benoit Coutu, Derek Hu, John Huk-sing Ip, Peter Noseworthy, Maria Leonor Parody, Farhad Rafii, Samuel Sears, JR, **Narendra Singh**, Bruce Sheldon Stambler, Naeem K. Tahirkheli, Juan F. Agudelo-Uribe Silvia Shardonofsky, David B. Bharucha, A. John Camm, Consistency And Predictiveness Of Conversion Among Multiple Episodes Of Paroxysmal Supraventricular Tachycardia (Psvt) Treated With Etripamil: Outcomes From Node-303 ACC Chicago 2025
71. James E. Ip, Benoit Coutu, Peter Noseworthy, Jonathan P. Piccini, Sean D. Pokorney, Narendra Singh, Bruce S. Stambler, David B. Bharucha, A. John Camm, Combined Efficacy, Safety, and Test Dose Tolerability of Etripamil for Acute Paroxysmal Supraventricular Tachycardia (PSVT) Across Multiple Clinical Trials AHA New Orleans 2025
72. James Edmund Ip, Peter Noseworthy, Maria Leonor Parody, Farhad Rafii, Samuel Sears, JR, **Narendra Singh**, Bruce Sheldon Stambler, Naeem K. Tahirkheli, Juan F. Agudelo-Uribe Silvia Shardonofsky, David B. Bharucha, A. John Camm, Minimal Blood Pressure Effects of Intranasal Etripamil for Paroxysmal Supraventricular Tachycardia, ACC New Orleans 2006

**NOTE: Publication list does not include multiple papers from multicenter clinical trials where authorship was given “...on behalf of the XXXXX Investigators”**

**Please see previous section for list of studies served as site principal investigator.**

**Highest impact publications are enclosed by a border box**